Sildenafil cheap buy

Figure 8: Plasma Vardenafil Concentration (Mean ± SD) Curve for a Single 20 mg LEVITRA Dose.

Vardenafil is rapidly absorbed with absolute bioavailability of approximately 15%.

Maximum observed plasma concentrations after a single 20 mg dose in healthy volunteers are usually reached between 30 minutes and 2 hours (median 60 minutes) after oral dosing in the fasted state.

Two food-effect studies were conducted which showed that high-fat meals caused a reduction in

Cmax

The mean steady-state volume of distribution (Vss) for vardenafil is 208 L, indicating extensive tissue distribution.

Vardenafil and its major circulating metabolite, M1, are highly bound to plasma proteins (about 95% for parent drug and M1). This protein binding is reversible and independent of total drug concentrations.

Following a single oral dose of 20 mg vardenafil in healthy volunteers, a mean of 0.00018% of the administered dose was obtained in semen 1.5 hours after dosing. Vardenafil is metabolized predominantly by the hepatic enzyme CYP3A4, with contribution from the CYP3A5 and CYP2C isoforms.

The major circulating metabolite, M1, results from desethylation at the piperazine moiety of vardenafil.

The plasma concentration of M1 is approximately 26% that of the parent compound. This metabolite shows a phosphodiesterase selectivity profile similar to that of vardenafil and an in vitro inhibitory potency for PDE5 28% of that of vardenafil. Therefore, M1 accounts for approximately 7% of total pharmacologic activity. The total body clearance of vardenafil is 56 L/h, and the terminal half-life of vardenafil and its primary metabolite (M1) is approximately 4-5 hours.

After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91-95% of administered

oral

LEVITRA is not indicated for use in pediatric patients. Vardenafil trials were not conducted in the pediatric population.

In a healthy volunteer study of elderly males (?65 years) and younger males (18–45 years), mean Cmax and AUC

were

In volunteers with mild hepatic impairment (Child-Pugh A), the Cmax and AUC following a 10 mg vardenafil dose were increased by 22% and 17%, respectively, compared to healthy control subjects.

In volunteers with moderate hepatic impairment (Child-Pugh B), the Cmax and AUC following a 10 mg vardenafil dose were increased by 130% and 160%, respectively, compared to healthy control subjects. Vardenafil has not been evaluated in patients with severe (Child-Pugh C) hepatic impairment.

[See DOSAGE AND ADMINISTRATION , WARNINGS AND PRECAUTIONS and Use In Specific Populations ] Renal Impairment. In male volunteers with CL cr = 50.80 mL/min, the pharmacokinetics of vardenafil were similar to those observed in a control group with CLcr >80 mL/min. In male volunteers with CL cr = 30.50 mL/min or CL cr 80 mL/min). Vardenafil pharmacokinetics have not been evaluated in patients requiring renal dialysis.

[See DOSAGE AND ADMINISTRATION , WARNINGS AND PRECAUTIONS and Use In Specific Populations ].

LEVITRA was evaluated in four major double-blind, randomized, placebo-controlled, fixed-dose, parallel design, multicenter trials in 2431 men aged 20-83 (mean age 57 years; 78% White, 7% Black, 2% Asian, 3% Hispanic and 10% Other/Unknown).

The doses of LEVITRA in these studies were 5 mg, 10 mg, and 20 mg. Two of these trials were conducted in the general erectile dysfunction (ED) population and two in special ED populations (one in patients with diabetes mellitus and one in post-prostatectomy patients).

LEVITRA was dosed without regard to meals on an as needed basis in men with ED, many of whom had multiple other medical conditions.

Primary efficacy assessment in all four major trials was by means of the Erectile Function (EF) Domain score of the validated International Index of Erectile Function (IIEF) Questionnaire and two questions from the Sexual Encounter Profile (SEP) dealing with the ability to achieve vaginal penetration (SEP2), and the ability to maintain an erection long enough for successful intercourse (SEP3).

In all four fixed-dose efficacy trials, LEVITRA showed clinically meaningful and statistically significant improvement in the EF Domain, SEP2, and SEP3 scores compared to placebo.

The mean baseline EF Domain score in these trials was 11.8 (scores range from 0-30 where lower scores represent more severe disease). LEVITRA (5 mg, 10 mg, and 20 mg) was effective in all age categories ( PATIENT INFORMATION. Read the Patient Information about LEVITRA before you start taking it and again each time you get a refill. You may also find it helpful to share this information with your partner. This leaflet does not take the place of talking with your doctor. You and your doctor should talk about LEVITRA when you start taking it and at regular checkups. If you do not understand the information, or have questions, talk with your doctor or pharmacist.

WHAT IMPORTANT INFORMATION SHOULD YOU KNOW ABOUT LEVITRA? LEVITRA can cause your blood pressure to drop suddenly to an unsafe level if it is taken with certain other medicines.

With a sudden drop in blood pressure, you could get dizzy, faint, or have a heart attack or stroke.

Do not take LEVITRA if you: Take any medicines called “nitrates” (often used to control chest pain, also known as angina). Use recreational drugs called “poppers” like amyl nitrate and butyl nitrate. Take riociguat (Adempas ® ), a guanulate cyclase stimulator, a medicine that treats pulmonary arterial hypertension and chronic-thromboembolic pulmonary hypertension. (See "Who Should Not Take LEVITRA?") Tell all your healthcare providers that you take LEVITRA . If you need emergency medical care for a heart problem, it will be important for your healthcare provider to know when you last took LEVITRA. LEVITRA is a prescription medicine taken by mouth for the treatment of erectile dysfunction (ED) in men. ED is a condition where the penis does not harden and expand when a man is sexually excited, or when he cannot keep an erection. A man who has trouble getting or keeping an erection should see his doctor for help if the condition bothers him.

LEVITRA may help a man with ED get and keep an erection when he is sexually excited.

LEVITRA does not: Cure ED Increase a man’s sexual desire Protect a man or his partner from sexually transmitted diseases, including HIV.

Speak to your doctor about ways to guard against sexually transmitted diseases.

When a man is sexually stimulated, his body’s normal physical response is to increase blood flow to his penis. LEVITRA helps increase blood flow to the penis and may help men with ED get and keep an erection satisfactory for sexual activity.

Once a man has completed sexual activity, blood flow to his penis decreases, and his erection goes away.

Talk sildenafil cheap buy to your doctor to decide if LEVITRA is right for you.

LEVITRA has been shown to be effective in men over the age of 18 years who have erectile dysfunction, including men with diabetes or who have undergone prostatectomy. Do not take LEVITRA if you: Take any medicines called “nitrates” (See “What important information should you know about LEVITRA?”). Angina is a symptom of heart disease and can cause pain in your chest, jaw, or down your arm. Medicines called nitrates include nitroglycerin that is found in tablets, sprays, ointments, pastes, or patches.

Nitrates can also be found in other medicines such as isosorbide dinitrate or isosorbide mononitrate. Some recreational drugs called “poppers” also contain nitrates, such as amyl nitrate and butyl nitrate.

Ask your doctor or pharmacist if you are not sure if any of your medicines are nitrates. Take riociguat, a guanylate cyclase stimulator, a medicine that treats pulmonary arterial hypertension and chronic-throembolic pulmonary hypertension.

Have been told by your healthcare provider to not have sexual activity because of health problems. Sexual activity can put an extra strain on your heart, especially if your heart is already weak from a heart attack or heart disease. WHAT SHOULD YOU DISCUSS WITH YOUR DOCTOR BEFORE TAKING LEVITRA? Before taking LEVITRA, tell your doctor about all your medical problems, including if you: Have heart problems such as angina, heart failure, irregular heartbeats, or have had a heart attack. Ask your doctor if it is safe for you to have sexual activity. Have low blood pressure or have high blood pressure that is not controlled. Or any family members have a rare heart condition known as prolongation of the QT interval (long QT syndrome). Have

retinitis

Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements.

Always check with your doctor before starting or stopping any medicines. Especially tell your doctor if you take any of the following: Medicines called nitrates (see “What important information should you know about LEVITRA?”). Ketoconazole or itraconazole (such as Nizoral ® or Sporanox ® ). Ritonavir (Norvir ® ) or indinavir sulfate (Crixivan ® ) saquinavir (Fortavase ® or Invirase ® ) or atazanavir (Reyataz ® ).

These include Hytrin ® (terazosin HCl), Flomax ® (tamsulosin HCl), Cardura ® (doxazosin mesylate), Minipress ® (prazosin HCl), Rapaflo ® (silodosin) or Uroxatral ® (alfuzosin HCl). Alpha-blockers are sometimes prescribed for prostate problems or high blood pressure.

In some patients the use of PDE5 inhibitor drugs, including LEVITRA, with alpha-blockers can lower blood pressure significantly leading to fainting. You should contact the prescribing physician if alpha-blockers or other drugs that lower blood pressure are prescribed by another healthcare provider.

These include quinidine, procainamide, amiodarone and sotalol. Some men can only take a low dose of LEVITRA because of medical conditions or medicines they take. Your doctor will prescribe the dose that is right for you. If you are older than 65 or have liver problems, your doctor may start you on a lower dose of LEVITRA. If you have prostate problems or high blood pressure, for which you take medicines called alpha-blockers, your doctor may start you on a lower dose of LEVITRA.

If you are taking certain other medicines your doctor may prescribe a lower starting dose and limit you to one dose of LEVITRA in a 72-hour (3 days) period. Take 1 LEVITRA tablet about 1 hour (60 minutes) before sexual activity. Some form of sexual stimulation is needed for an erection to happen with LEVITRA. Do not change your dose of LEVITRA without talking to your doctor.

Your doctor may lower your dose or raise your dose, depending on how your body reacts to LEVITRA.

Call your doctor or emergency room immediately if you accidentally took more LEVITRA than prescribed.

The most common side effects with LEVITRA are headache, flushing, stuffy or runny nose, indigestion, upset stomach, dizziness or back pain. These side effects usually go away after a few hours.

Call your doctor if you get a side effect that bothers you or one that will not go away.

LEVITRA may uncommonly cause: An erection that won’t go away (priapism).

If you get an erection that lasts more than 4 hours, get medical help right away.

Priapism must be treated as soon as possible or lasting damage can happen to your penis including the inability to have erections. Color vision changes, such as seeing a blue tinge to objects or having difficulty telling the difference between the colors blue and green.

In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, including LEVITRA) reported a sudden decrease or loss of vision in one or both eyes. It is uncertain whether PDE5 inhibitors directly cause the vision loss. If you experience sudden decrease or loss of vision, stop taking PDE5 inhibitors, including LEVITRA, and call a doctor right away. Sudden loss or decrease in hearing, sometimes with ringing in the ears and dizziness, has been rarely reported in people taking PDE5 inhibitors, including LEVITRA. It is not possible to determine whether these events are related directly to the PDE5 inhibitors, to other diseases or medications, to other factors, or to a combination of factors.

If you experience these symptoms, stop taking LEVITRA and contact a doctor right away.

For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You may report side effects to FDA at 1800-FDA-1088.

Store sildenafil 200mg for sale LEVITRA at room temperature between 59–86° F (15–30° C). Keep LEVITRA and all medicines out of the reach of children.

Medicines are sometimes prescribed for conditions other than those described in patient information leaflets. Do not use LEVITRA for a condition for which it was not prescribed.

Do not give LEVITRA to other people, even if they have the same symptoms that you have. This leaflet summarizes the most important information about LEVITRA. If you would like more information, talk with your healthcare provider.

You can ask your doctor or pharmacist for information about LEVITRA that is written for health professionals.

For more information you can also visit www.LEVITRA.com, or call 1-866-LEVITRA. Inactive Ingredients: microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and red ferric oxide. Tadalafil and vardenafil vs sildenafil: a review of patient?preference studies. Volume 107 Issue 7 BJU International pages: 1166-1166 First Published online: March 25, 2011.

Department of Urology, University Federico II of Naples, Ely Lilly Italy, Florence, and.

Department of Urology, University Federico II of Naples, Ely Lilly Italy, Florence, and. Department of Urology, University Federico II of Naples, Ely Lilly Italy, Florence, and.

Department of Urology, University Federico II of Naples, Ely Lilly Italy, Florence, and.

Department of Urology, University Vita Salute San Raffaele, Milan, Italy. Department of Urology, University Federico II of Naples, Ely

Lilly

Department of Urology, University Federico II of Naples, Ely Lilly Italy, Florence, and. Department of Urology, University Federico II of Naples, Ely Lilly Italy, Florence, and.

Department of Urology, University Vita Salute San Raffaele, Milan, Italy. The immediate objective of phosphodiesterase type 5 (PDE5) inhibitor treatment is to restore the ability of a man to achieve and/or maintain an erection adequate for sexual intercourse.

As erectile dysfunction (ED) generally develops in the second half of life, the ultimate objective generally is not procreation, but quality of sexual life.

Indeed, ED is known to impair quality of life considerably; two?thirds of men report that ED has impaired their self?esteem and nearly a third claim that it has damaged the relationship with their partner. It follows that the therapeutic success of PDE5 inhibition has an important subjective component, which is compounded by the subjective nature and complexity of sexual life in humans.

This makes it very

difficult

therapy

The acknowledgement that the patient has an important role in therapeutic decisions for ED has fuelled interest in the concept of patient preference.

It has been established that patient preference depends on three factors, i.e.

age, duration of ED, frequency and dynamics of sexual relations, and the characteristics of their partners, e.g. age, menopausal status and level of interest in sexual activity and medication profile. Medication features of interest include efficacy in terms of quality of erection, consistency of effects, rapid onset of action, long duration of action, side?effect profile and route of administration; drug costs must also be considered if the medicinal product is not reimbursed.

After explaining why patient preference is an important endpoint for assessing a phosphodiesterase type 5 (PDE5) inhibitor, we review the quality of published patient?preference studies and the data related to the reasons for the preference of one compound over another.